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Objectives: Surgical and non-surgical management options with pre-treat-
ment biopsy are available for small renal masses (SRMs). The cost-effectiveness 
of these options is unclear. This study aimed to systematically review the cost-
effectiveness of various management options for SRMs, and evaluate these cost-
effectiveness studies. MethOds: A systematic literature review was conducted 
on five databases from inception to December 31, 2014. Search terms consisted 
of three categories of keywords, e.g., ‘economic evaluation’, ‘renal mass’ and 
‘surgery’. Inclusion criteria were 1) original research, 2) full economic evalu-
ation of management options for SRMs, 3) written in English, and 4) with tar-
geted populations aged ≥ 18 years old. Exclusion criteria were 1) investigation of 
metastases only, and 2) case reports etc. Manual search of relevant bibliographies 
was performed. Eligible studies were evaluated using the Consolidated Health 
Economic Evaluation Reporting Standards (CHEERS). Results: Among the 557 
articles retrieved, 6 were included, all of which were cost-utility analyses and 
used Markov models with a lifetime horizon except for one study that adapted a 
10-year horizon. One to three items on the CHEERS checklist were unfulfilled for 
each study. Three studies were from a societal perspective whereas the others 
were from a payer’s perspective. Health states included no evidence of disease, 
recurrence, metastases and death. Transition probabilities were obtained from 
observational studies. Evaluated strategies were surveillance, ablation, and partial 
and radical nephrectomy with/without pre-treatment biopsy. Two studies deter-
mined that pre-treatment biopsy was dominant while two studies found that 
laparoscopic partial nephrectomy was the optimal strategy. The remaining two 
studies concluded that ablation was preferred. cOnclusiOns: The evidence of 
cost-effectiveness of management options for SRMs is limited. The findings of the 
available studies are inconclusive. Large, prospective, randomized clinical trials 
assessing various competing strategies in the management of SRMs are needed 
to inform better decision-making for physicians and patients.
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Objectives: Kidney transplant recipients (KTRs) must manage several self-care 
behaviors. They have to take multiple daily medications, look for signs of acute 
rejection, have frequent blood draws and often manage additional chronic condi-
tions. There is limited understanding of underlying behavioral factors that may 
influence KTRs’ adherence to self-care behaviors. This study aims to explore 
the association between self-efficacy, health literacy and adherence to self-care 
behaviors and to describe variations of self-efficacy based on individual KTRs’ 
characteristics. MethOds: KTRs who were 1 to 5 years post-transplant, over the 
age of 18 at the time of transplants and had a single organ transplant were eligible. 
Four hundred and thirty-five eligible KTRs received a mailed survey inquiring 
about self-efficacy, health literacy, medication adherence, and self-care behav-
iors. Self-efficacy was tested as a mediator or as a moderator of health literacy 
on adherence to self-care behaviors. Linear regression analyzed variations of 
self-efficacy in KTRs. Results: One hundred and eighty-two KTRs completed 
the survey (42% participation rate). Mean age of responders was 59.5 (+/-12.1) 
years; 61.0% were male; and 38.1% were African American. The mean time since 
transplant was 38.0 (+/-18.1) months. African Americans had lower self-efficacy 
compared to other patient groups (β = -0.61, p= 0.03). An increase in functional 
health literacy was associated with an increase in self-efficacy (β = 0.72, p< 0.01). 
Self-efficacy was a partial mediator of functional and communicative health 
literacy on adherence to self-care behaviors (functional: α β = 0.32, CI: 0.11-0.60; 
communicative: α β = 0.37, CI: 0.11-0.71). cOnclusiOns: This study provides 
new insights into the factors influencing KTRs’ adherence to self-care behav-
iors. Clinicians need to monitor patients with low self-efficacy and low health 
literacy. The teach-back method and frequent communication can help increase 
self-efficacy. Use of larger font, photos and visual cues will help patients with 
limited health literacy. These methods may optimize KTRs’ adherence to self-care 
behaviors.
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Objectives: To evaluate and compare the medication adherence rate among the 
patients undergoing maintenance Hemodialysis at different hospital setups in 
India. MethOds: A prospective comparative study was conducted at academic, 
corporate and government hospitals after the approval of protocol by the Ethics 
Committee. The patients on hemodialysis of both gender aged between 18-75 
years were enrolled in the study after obtaining the written informed consent 
from the patients. The validated medication adherence rating scale was used 
to evaluate the adherence among the patients. The medication adherence rate 
was scored from 0–8 with higher scores representing better adherence. ANOVA 
test was used to assess the difference in mean scores in medication adherence 
rating among three hospitals patients with p value less than 0.05 was consid-
ered as statistically significant. Results: A total of 200 patients were recruited 
in the study. Out of 200 patients, 104 from academic hospital, 70 from corpo-
rate hospital and 26 from government hospital. The mean age and vintage of 
hemodialysis of the study population were 51.56 years and 41.75 months. 
study (65, 57 in G1-4 and G5 groups, respectively). The mean±SD age of the patients 
was 52.9±7.8 years. Mean±SD monthly cost of illness for the patients on in G1-4 
stages and G5 stage were INR 7882±945 ($127) and INR 13882±1687 ($224), respec-
tively. The mean±SD monthly COI for the patients on dialysis was INR 32171±950 
($519). Of total expenditure 55.4% were spent directly for treating illness (out of 
pocket expenditure). On average a patient on dialysis had spent 3.9 lakh INR per 
year ($6291). Through analysis of sub-groups of patients, it was found that fund-
ing from employer/ Insurance, dialysis, lower socioeconomic status, lower educa-
tion, comorbidities and rural residential have a major impact on COI in patients of 
chronic kidney disease. cOnclusiOns: Monthly cost of illness for the patients in 
G1-G4 and G5 were INR 7882 ($127) and INR 13882 ($224). The study is in progress.
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Objectives: The Lack of Adherence to Immunosuppressive Treatment (LAIT) has 
been associated with Chronic Humoral Rejection (CHR) and decreased graft survival. 
The objective of the present study was to estimate the direct healthcare costs asso-
ciated with the LAIT in Spanish Kidney Transplant (KT) patients. MethOds: A sys-
tematic literature review and survey of 6 KT experts were carried out to identify the 
relevant healthcare resource use associated with suspected LAIT, suspected kidney 
CHR, confirmed CHR and graft loss. Subsequently two economic models were devel-
oped from a Spanish National Health Service perspective: the first using an incidence 
approach (annual cost associated with LAIT according to the incidence of KT patients 
in the year 2013) and the second using a prevalence approach (total costs associated 
with LAIT due to the number of kidney transplanted patients). A sensitivity analysis 
was also performed. Results: According to the incidence approach, the annual cost 
associated with LAIT in Spain is 12,296,243€ , where 80% is driven by graft loss and 
the patient returning to dialysis. The mean cost per non-adherent patient is 18,121€ . 
According to the prevalence approach, out of 25,600 KT patients in Spain (2013), LAIT 
would occur in 6,785 (26.5%) patients, resulting in 705 graft losses. The estimated 
total costs associated with LAIT adds up to 127,224,726€ consisting of 102,647,488€ 
being related to graft loss and return to dialysis; 13,395,015€ due to confirmed CHR; 
9,742,735€ related to suspected CHR; and 1,439,487€ due to LAIT. cOnclusiOns: 
Considering the total number of KT patients in Spain during 2013, the economic 
burden due to lack of adherence to immunosuppressive treatment exceeds 127 mil-
lion Euros, and this figure does not include societal costs. According to our results 
(incidence approach) and considering data from a previous published study, LAIT 
represents 7.1% of healthcare costs associated with the treatment of KT patients.
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Objectives: Kidney transplantation remains limited by toxicities of calcineurin 
inhibitors (CNIs). Belatacept is a less toxic therapeutic alternative, but its cost lim-
its its use. Whether the reduction of renal post-transplant hospitalization balance 
this higher cost has been addressed in two situations: 1- in first line therapy 2- as a 
second line immunosuppressant for CNIs intolerant patients. MethOds: A Cost-
minimization analysis has been performed for 2 groups of patients: Group 1- 7 
Belatacept-treated patients paired to 21 Tacrolimus-treated patients (1:3) over 5 
years post-transplant. Group 2- 12 patients having received transplantation, one 
year before and after their shift from CNI to Belatacept. The study has been con-
ducted from The French Health Insurance (FHI) perspective. Treatment-associated 
costs (based on FHI and hospital purchasing prices) and hospitalization DRG’s costs 
(collected from PMSI database) were compared by a modified Friedman’s proce-
dure and a Wilcoxon rang test, respectively. Results: In both cohorts, the cost 
of belatacept treatment and administration was more expensive than CNIs treat-
ment, dosage and follow-up but there were fewer unscheduled hospitalizations 
with belatacept: Group 1: 69478US$ vs 14900US$, 11±10 vs 17±15 days Group 2: 
14031US$ vs 3778US$, 22±8 vs 50±50 days Taking into account treatment and hos-
pitalization costs over five years on the first cohort remained significantly higher 
with Belatacept as compared to CNIs: 90324US$ versus 38792US$ whereas the shift 
to Belatacept reduced this amount from 54720US$ to 36667US$ over 1 year, so a 
40% decrease of post-transplant management costs. Heterogeneity of the drug 
response and the low number of patients prevented these differences to be statis-
tically significant but belatacept treated patients cohort are sparse. cOnclusiOns: 
This economic analysis shows that beyond potential therapeutic advantages and 
reduction of unscheduled post-transplant hospitalizations, the place of the drug 
in a therapeutic flow chart must include the cost-minimization approach to allow 
patients best healthcare‘s management nowadays.
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